Go Pro
NASDAQ:REVB

Revelation Biosciences Q1 2025 Earnings Report

Revelation Biosciences logo
$1.10 +0.01 (+0.92%)
Closing price 08/24/2026 03:58 PM Eastern
Extended Trading
$1.10 0.00 (0.00%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revelation Biosciences EPS Results

Actual EPS
-$25.32
Consensus EPS
-$82.56
Beat/Miss
Beat by +$57.24
One Year Ago EPS
N/A

Revelation Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Revelation Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Revelation Biosciences' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Revelation Biosciences Earnings Headlines

Equities Analysts Set Expectations for REVB Q3 Earnings
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
REVB Poised for Big Year
See More Revelation Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email.

About Revelation Biosciences

Revelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

View Revelation Biosciences Profile